scholarly journals Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from SHIV acquisition by long-acting cabotegravir in macaques

AIDS ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Sundaram Ajay Vishwanathan ◽  
Chunxia Zhao ◽  
Roopa Luthra ◽  
George K. Khalil ◽  
Monica M. Morris ◽  
...  
Keyword(s):  
Sexually Transmitted Infections ◽  
Medroxyprogesterone Acetate ◽  
Sexually Transmitted ◽  
Depot Medroxyprogesterone Acetate ◽  
Impact Protection ◽  
Long Acting

scholarly journals Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant

2020 ◽  
pp. sextrans-2020-054590
Author(s):  
Jennifer Deese ◽  
Neena Philip ◽  
Margaret Lind ◽  
Khatija Ahmed ◽  
Joanne Batting ◽  
...  
Keyword(s):  
Sexually Transmitted Infections ◽  
Medroxyprogesterone Acetate ◽  
Contraceptive Use ◽  
Intrauterine Device ◽  
Secondary Analysis ◽  
Final Visit ◽  
Sexually Transmitted ◽  
Depot Medroxyprogesterone Acetate ◽  
Copper Iud ◽  
Copper Intrauterine Device

ObjectivesReproductive aged women are at risk of pregnancy and sexually transmitted infections (STI). Understanding drivers of STI acquisition, including any association with widely used contraceptives, could help us to reduce STI prevalence and comorbidities. We compared the risk of STI among women randomised to three contraceptive methods.MethodsWe conducted a secondary analysis to assess the risk of chlamydia and gonorrhoea in a clinical trial evaluating HIV risk among 7829 women aged 16–35 randomised to intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper intrauterine device (IUD) or a levonorgestrel (LNG) implant. We estimated chlamydia and gonorrhoea prevalences by contraceptive group and prevalence ratios (PR) using log-binomial regression.ResultsAt baseline, chlamydia and gonorrhoea prevalences were 18% and 5%, respectively. Final visit chlamydia prevalence did not differ significantly between DMPA-IM and copper IUD groups or between copper IUD and LNG implant groups. The DMPA-IM group had significantly lower risk of chlamydia compared with the LNG implant group (PR 0.83, 95% CI 0.72 to 0.95). Final visit gonorrhoea prevalence differed significantly only between the DMPA-IM and the copper IUD groups (PR 0.67, 95% CI 0.52 to 0.87).ConclusionsThe findings suggest that chlamydia and gonorrhoea risk may vary with contraceptive method use. Further investigation is warranted to better understand the mechanisms of chlamydia and gonorrhoea susceptibility in the context of contraceptive use.

Contraception Insurance Coverage and Receipt of Long-Acting Reversible Contraception or Depot Medroxyprogesterone Acetate on the Day of Abortion

2017 ◽  
Vol 130 (1) ◽  
pp. 109-117 ◽  
Author(s):  
Jamie W. Krashin ◽  
Gretchen S. Stuart ◽  
Joanne Garrett ◽  
Hannah Spector ◽  
Amy G. Bryant ◽  
...  
Keyword(s):  
Medroxyprogesterone Acetate ◽  
Insurance Coverage ◽  
Depot Medroxyprogesterone Acetate ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document